BioLife Solutions, Inc.（BLFS）資訊與事件BLFSBioLife Solutions, Inc.

Major Averages Mixed as Oil Prices Surge Again

The major averages were mixed near noon as traders take a cautious approach ahead of key earnings reports due from Alphabet, Tesla and IBM after the closing bell. Alphabet's report in particular will provide another major test of whether companies' heavy investments in artificial intelligence continue to generate meaningful returns and investors will closely scrutinize Alphabet's AI monetization strategy and cloud growth.Meanwhile, oil prices were surging once again as escalating tensions in the Middle East raise concerns over potential supply disruptions. Reports that two Saudi oil tankers altered their routes in response to Houthi threats in the Red Sea have added to fears that higher energy prices could reignite inflation pressures and complicate the Federal Reserve's policy outlook.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AT&Treportedand reiterated its FY26 outlookGE Vernovareportedand raised its FY26 revenue guidanceAMDannounced aas part of a partnership to deploy up to 2 GW of AMD Instinct GPUsRepligenBioLife Solutionsfor $31 per share, or $1.5BPhilip Morrisreportedand cut its FY26 earnings outlook2. WALL STREET CALLS:CoreWeaveto Buy at Truist after 42% pullbackPegasystemsto Market Perform at CitizensCircle Internetwith a Market Perform at Raymond JamesStifelDigitalOceanon selloff, positive data pointsTrimbleto Market Perform at Raymond James3. AROUND THE WEB:Meta'sinternal AI incubator is developing an AI model router, similar to OpenRouter's, to cut costs by sending some AI tasks to lower-cost models, The Information saysNews Corphas countersued Brave Software, alleging the company illegally scraped and sold Wall Street Journal and New York Post articles to AI companies, arguing the practice constitutes copyright infringement rather than fair use, Reuters reportsThe University of Tennessee Research Foundation sued Anthropic in Delaware federal court, arguing the company infringed its patents related to neural networks, Reuters saysPlatinum Equity is close to acquiring a 50% stake in Nestle'sEuropean water business through a joint venture that would value the San Pellegrino and Perrier owner at nearly EUR 5B, FT reportsAmgenhas reached a $74M settlement of a lawsuit accusing the company of waiting too long to disclose that it might owe the U.S. Internal Revenue Service $10.7B for underreporting six years of taxes, Reuters says4. MOVERS:Super Microgains afterArrowheadincreases after announcing its Phase 3 SHASTA-3 and SHASTA-4 studiesAirJoulehigher after announcing with Kubota Corporationanof its water-from-air technology in Texas and CaliforniaAdtranlower afterfor Q2 and Q3Dyne Therapeutics (DYN) falls after announcing a5. EARNINGS/GUIDANCE:Rogers Communications, with CEO Tony Staffieri saying the results "reflect strong execution"Moody'sand narrowed its guidance for FY26Teledyneand provided guidance for Q3 and FY26RPM, with EPS and revenue beating consensusTravel + Leisure, with CEO Michael Brown calling it "another strong quarter"INDEXES:Near midday, the Dow was up 0.33%, or 174.51, to 52,399.15, the Nasdaq was down 0.04%, or 10.89, to 25,826.32, and the S&P 500 was up 0.16%, or 11.77, to 7,520.97.

Repligen to Acquire BioLife Solutions for $1.5 Billion

Repligen (RGEN) and BioLife Solutions (BLFS) announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5B, comprised of 64% in Repligen common stock and 36% in cash. The directors of each company unanimously approved the Transaction. BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share. This represents an implied premium of 24% to 90-day volume-weighted average price for the period ended July 21, 2026. The Transaction is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals, approval by BioLife stockholders, and the satisfaction of other customary closing conditions set forth in the merger agreement. The Transaction is expected to be accretive to Repligen's top-line growth, adjusted margins, and adjusted earnings per share by at least 5c in year one and at least 25 cents in year two. Repligen expects at least $20M of synergies in year one and at least $30M in year two from eliminating public-company costs, G&A efficiencies, and manufacturing and supply-chain optimization. While this combination is expected to generate important cross-selling opportunities, Repligen's financial expectations only assume modest revenue synergies leaving the potential for future upside. The cash component of the merger consideration will be funded with cash on hand. Repligen's balance sheet is expected to remain healthy with greater than $300M of pro forma cash and cash equivalents, preserving optionality for additional M&A and other investment opportunities.